RBM39 and neuroblastoma: We and others have shown that targeting the splicing factor RBM39 by indisulam, a ‘molecular glue’ that bridges RBM39 to E3 ubiquitin ligase DCAF15 for proteasomal degradation, achieved significant anti-tumor activity in neuroblastoma models (Singh et al., 2021; Nijhuis et al., 2022).